Studio Health is conducting a research study on behalf of Pfizer to better understand how migraine affects people in the workplace and to explore whether education can improve awareness and understanding of the condition.
The study is open to Pfizer employees in the United States. You do not need to have migraine to take part.
Participation may include:
The purpose of the study is to understand how migraine impacts the workplace, how much employees know about the condition, and what improvements could be made to support people affected by migraine.
Your participation is entirely voluntary. Your decision to take part or not take part will not affect your employment in any way.
This Project Privacy Notice explains how Studio Health uses your personal data for this study. It should be read alongside the Study Informed Consent Document (ICD).
Studio Health (ICO Registration Number ZB019722) is responsible for collecting and using personal data for this study.
Pfizer is the study sponsor and is separately responsible for the information it receives and uses in connection with the study.
If you have any questions about this notice or how your personal data is used, please contact:
As part of this study, we may collect the following information:
We use your information to:
We will not use your information for marketing purposes or to make decisions about your employment.
Study findings, insights and outputs will be reported in aggregated or anonymised formats and will not identify individual participants. This may include sponsor reports, publications, conference materials and future research outputs.
We process your personal data under the following lawful bases:
Where consent is relied upon, you may withdraw your consent at any time by contacting us using the details above. Withdrawal will not affect processing already carried out. Please note that where data has already been anonymised or incorporated into aggregated research findings, it may not be possible to remove it following withdrawal.
We share personal data only where necessary and with:
We only share the minimum amount of personal data necessary for each purpose.
Some of these providers may process personal data outside the UK or European Economic Area (EEA), including in the United States. Where this occurs, appropriate safeguards will be implemented to protect your personal data.
Studio Health will retain identifiable personal data collected as part of this study for no longer than six months after the study has ended.
Following this period, personal data will be anonymised so that it can no longer be linked to you. Once anonymised, the information is no longer considered personal data and may be retained and used for research purposes indefinitely.
At the end of the study, Studio Health will provide study data to Pfizer. Pfizer will retain the pseudonymised study dataset for up to 15 years to support research, regulatory and compliance requirements. After this period, Pfizer may anonymise the data and retain it for research purposes.
You have a number of rights in relation to your personal data, including the right to request:
Where we rely on consent to process your personal data, you also have the right to withdraw that consent at any time.
Further information about your rights can be found in the Studio Health Privacy Notice or on the Information Commissioner’s Office website:
To exercise any of your rights, please contact:
research@studio-health.com
If you have any concerns about how we collect and use your personal data, we encourage you to contact us in the first instance so that we can investigate and resolve your concern promptly.
We will acknowledge receipt of your complaint as soon as possible and no later than 30 days, and aim to respond within a reasonable timeframe in accordance with applicable data protection requirements.
If you are not satisfied with our response, you have the right to lodge a complaint with the Information Commissioner’s Office (ICO). Further information is available at:
We may update this Project Privacy Notice from time to time. The latest version will always be made available to participants through the study team or the Studio Health website.